Skip to content

The Effect of RECO-18 on Infertile Women Undergoing in Vitro Fertilization-embryo Transfer

A Pilot Study of the Effect of RECO-18 Containing Natural Plant Extracts on Infertile Women Undergoing in Vitro Fertilization-embryo Transfer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05412147
Enrollment
80
Registered
2022-06-09
Start date
2022-07-31
Completion date
2023-04-30
Last updated
2022-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Disorders, Infertility, Female

Keywords

pregnancy rate, in vitro fertilization-embryo transfer

Brief summary

How to improve the fertility of infertile women has become a hot topic in the field of assisted reproduction. Animal experiment has shown that RECO-18 significantly improved the female fertility in mice, and the specific mechanism was related to reducing follicular atresia, promoting follicle development and improving oocyte quality. Therefore the investigators aim to conduct a pilot study to explore the effect of RECO-18 in infertile women undergoing assisted reproduction treatment. This study is a prospective, randomized, controlled clinical study. The treatment group takes RECO-18 while the control group takes the multi-vitamins. The primary indicator is the ongoing pregnancy rate at 12 weeks' gestation; the secondary indicators are the number of oocytes retrieved, the normal fertilization rate and the rate of high quality embryos, implantation rate, clinical pregnancy rate, and early miscarriage rate.

Detailed description

Mitochondrial function is closely related to oocyte quality in female. Deficiency of multiple micronutrients is common in infertile women, and supplementation with multiple micronutrients has antioxidant effects to reduce the damage of oxidative stress to fertility, and helps to improve the outcomes of assisted reproductive treatment. RECO-18 is a functional food containing a variety of plant extracts and enzymatic soy phospholipids. In in vivo and in vitro senescent models, the investigators found RECO-18 to improve oocyte quality mainly by regulating the mitochondrial apoptosis pathway. The investigators also found RECO-18 significantly improved the fertility of mice, and the specific mechanism was related to reducing follicular atresia, promoting follicle development and improving oocyte quality. Based on the animal experiments, the investigators intend to conduct a clinical trial to explore whether RECO-18 plays a role in improving oocyte and embryo quality and pregnancy outcomes in infertile women undergoing in vitro fertilization-embryo transfer.

Interventions

DIETARY_SUPPLEMENTRECO-18

4 pills daily, oral

DIETARY_SUPPLEMENTMulti-vitamins

one tablet daily, oral

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* female, 20 to 40 years old * the 1st or 2nd cycle of IVF/ICSI treatment * BMI≤30Kg/m2 * with bilateral ovaries * be eligible for IVF/ICSI treatment

Exclusion criteria

* Repeated implantation failures (with previous 3 or more IVF/ICSI failures) * moderate to severe endometriosis * untreated hydrosalpinx * untreated endometrial disease * contraindications for assisted reproductive techniques or gestation * a history of ovarian surgery * expected poor ovarian response (POR) or previous POR * polycystic ovarian syndrome * participants in clinical trials of other drugs within one month prior to enrollment; • hypersensitivity to follicle-stimulating hormone α, FSH, human menopausal gonadotropin, LH or excipients * uncontrolled endocrine diseases (such as hyperthyroidism, hypothyroidism, adrenal gland disease, obesity, etc.) * percutaneous epididymal sperm aspiration or testicular sperm aspiration

Design outcomes

Primary

MeasureTime frameDescription
Ongoing pregnancy rate at 12 weeks' gestationAt 12 weeks' gestationGestational sac with embryocardia-beat detected on ultrasound at 12 weeks' gestation

Secondary

MeasureTime frameDescription
Number of retrieved oocytesTwo weeks after oocyte retrievalTotal number of retrieved oocytes

Other

MeasureTime frameDescription
The rate of high quality embryosTwo weeks after oocyte retrievalNumber of high quality embryos / number of normal fertilized and cleavaged embryos
Clinical pregnancy rateFour to five weeks after embryo transferGestational sacs detected on ultrasound four to five weeks after embryo transfer
early miscarriage rateAt 12 weeks' gestationMisscarriage within 12 weeks' gestation
Implantation rateFour to five weeks after embryo transferNumber of gestational sac / number of transferred embryos
The normal fertilization rateTwo weeks after oocyte retrievalThe rate of fertilization with two pronuclear

Contacts

Primary ContactYu Li, doctor
liyuliyu0922@163.com13660141860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026